Identifying mutations that affect treatment response in advanced breast cancer
Official title: Novel estrogen receptor mutations as a biomarker dictating therapy response in advanced endocrine-resistant estrogen receptor-positive breast cancer
Funded at Johns Hopkins University · NIH-10954053 · Data updated 2026-11-12
This study is looking at how certain changes in estrogen receptors might affect how well treatments work for advanced breast cancer, and it hopes to help personalize therapy options for patients by identifying these changes in their tumors.
Quick facts
| Grant type | R03 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Johns Hopkins University NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project start | July 1, 2024 |
| Project end | June 30, 2026 |
| Funding year | 2024 |
| Award (this year) | $163,750 |
| NIH project number | 1R03CA293120-01 |
| Project ID | NIH-10954053 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with advanced estrogen receptor-positive breast cancer who have shown resistance to standard endocrine therapies.
✕Less likely to help
Patients with early-stage breast cancer or those who do not have estrogen receptor-positive tumors may not benefit from this research.
What this research studies
This research investigates how specific mutations in estrogen receptors can influence the effectiveness of therapies for advanced estrogen receptor-positive breast cancer. By analyzing tumor samples from patients with treatment-resistant cancer, the study aims to identify novel mutations that may serve as biomarkers for predicting therapy response. The approach includes advanced sequencing techniques to characterize these mutations and their impact on treatment outcomes. Patients may benefit from a more personalized treatment strategy based on their unique tumor mutations.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with advanced breast cancer who currently have limited responses to existing therapies.
How similar studies have gone: Previous research has shown success in identifying biomarkers for therapy response in breast cancer, suggesting that this approach may yield valuable insights.
Where this research is happening
-
Johns Hopkins University
Baltimore, United States Active
Researchers
- Principal investigator: Nayar, Utthara — Johns Hopkins University
- Study coordinator: Nayar, Utthara
Related research
Other NIH-funded projects on the same topics.
-
Improving Breast Cancer Guideline Adherence in Nigeria
Aimed at helping doctors in Nigeria follow international guideline-based breast cancer care to improve outcomes for women with breast cancer.
-
Genomic study to understand how genetics and epigenetics shape triple-negative breast cancer in African ancestry
This study looks at how inherited genes and gene activity affect triple-negative breast cancer in people of African ancestry to better understand why outcomes can be worse.
-
Translational breast cancer research to improve treatment options
A comprehensive program at Baylor College of Medicine is focusing on breast cancer; researchers will advance targeted therapies and biomarkers to help patients with aggressive or hard-to-treat forms.
-
Cancer Pain Management for Asian American Breast Cancer Survivors with Depressive Symptoms
A technology-based program helps Asian American breast cancer survivors with depressive symptoms manage chronic pain more effectively from home using a web app and mobile tools.
-
Co-Targeting IL-6 and CDK4/6 to Prevent TNBC in Women Veterans
A study aims to block two cancer-promoting pathways (IL-6 and CDK4/6) to prevent or reduce progression of triple-negative breast cancer in women veterans.
-
Gut bacteria and metabolites linked to breast density and cancer risk
A small, patient-friendly study will explore whether gut bacteria and their byproducts are connected to high breast density, which can raise cancer risk and make screening less accurate.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.